Fatal pneumonia associated with temozolomide therapy in patients with malignant glioma

Japanese Journal of Clinical Oncology

Volumn 42, Issue 7, 2012, Pages 632-636

  Hayashi, Hiroki ^a   Saito, Yoshinobu ^a   Kokuho, Nariaki ^a   Morimoto, Taisuke ^a,b   Kobayashi, Kenichi ^a   Tanaka, Toru ^a   Abe, Shinji ^a   Fujita, Kazue ^a   Azuma, Arata ^a   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Heisei Tateisi Hospital   (Japan)

Author keywords

Fatal pneumonia; Malignant glioma; Pneumocystis pneumonia; Temozolomide

Indexed keywords

METHYLPREDNISOLONE; PIPERACILLIN PLUS TAZOBACTAM; SULFAMETHOXAZOLE; TEMOZOLOMIDE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CAUSE OF DEATH; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTENSIVE CARE; MAINTENANCE THERAPY; MALE; PNEUMOCYSTIS PNEUMONIA; STEROID THERAPY; THORAX RADIOGRAPHY;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DRUG LABELING; FATAL OUTCOME; FEMALE; GLIOMA; HAEMOPHILUS INFLUENZAE; HUMANS; IMMUNOCOMPROMISED HOST; JAPAN; MALE; MIDDLE AGED; PNEUMOCYSTIS JIROVECII; PNEUMONIA; PNEUMOTHORAX; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 84864374919     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys058     Document Type: Article

References (21)

1. Thomas Jr CF, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98.
2. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100:663-71.
3. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995, comparison of HIV-associated cases to other immunecompromised states. Chest 2000;118:704-11.
4. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002;34:1098-107.
5. Tasaka S, Tokuda H, Sakai F, et al. Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. Intern Med 2010;49:273-81.
6. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
7. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
8. Yu SK, Chalmers AJ. Patients receiving standard-dose temozolomide therapy are at risk of Pneumocystis carinii pneumonia. Clin Oncol (R Coll Radiol) 2007;19:631-2.
9. Webb WR, Müller NL, Naidich DP. High-resolution CT of the Lung. 4th edn. Philadelphia: Lippincott Williams & Wilkins 2009;436-43.
10. Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1(→3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996;3:197-9.
11. Hamada H, Kohno N, Yokoyama A, et al. KL-6 as a serologic indicator of Pneumocystis carinii pneumonia in immunocompromised hosts. Intern Med 1998;37:307-10.
12. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007;131:1173-80.
13. Nakamura H, Tateyama M, Tasato D, et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med 2009;48:195-202.
14. Su YB, Sohn S, Krown SE, et al. Selective CD4{thorn} lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004;22:610-6.
15. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005;62:1423-6.
16. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996;27:235-40.
17. Kocher M, Frommolt P, Borberg SK, et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 2008;184:572-9.
18. Enomoto T, Azuma A, Kohno A, et al. Differences in the clinical characteristics of Pneumocystis jirovecii pneumonia in immunocompromised patients with and without HIV infection. Respirology 2010;15:126-31.
19. Limper AH, Offord KP, Smith TF, Martin WJ, 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989;140:1204-9.
20. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011;11:76.
21. Roblot F, Godet C, Le Moal G, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002;21:523-31.